High Hematocrit on TRT: What to Do When Your Red Blood Count Gets Too High

Of all the side effects associated with testosterone replacement therapy, elevated hematocrit is the most common reason a physician pauses or reduces treatment. It shows up on labs, looks alarming, and often triggers an overreaction — dose cuts or treatment stops that leave patients back where they started.

The reality is more nuanced. TRT-induced erythrocytosis (secondary polycythemia) is common, usually manageable, and often correctable through protocol adjustments without stopping treatment. Understanding what's happening physiologically — and what actually matters clinically — makes the difference between managing TRT well and cycling through unnecessary interruptions.

What Causes Hematocrit to Rise on TRT?

Testosterone stimulates erythropoiesis — the production of red blood cells — by stimulating kidney production of erythropoietin (EPO), the hormone that signals bone marrow to make more RBCs. This is the same mechanism by which athletes have historically blood-doped with EPO or testosterone: more testosterone → more EPO → more red blood cells → higher hematocrit.

On therapeutic TRT, this effect is milder than performance-doping doses but still clinically meaningful. For most men, hematocrit rises 2–6 percentage points during the first 6–12 months on TRT. Some men stabilize. Others continue rising.

Factors that increase hematocrit elevation risk: - Higher testosterone doses (more substrate for EPO stimulation) - Infrequent injections (higher peaks → more acute EPO stimulus) - Intramuscular vs. subcutaneous (IM produces higher peaks) - Sleep apnea (independent cause of erythrocytosis — often underdiagnosed) - Dehydration (hemoconcentrates blood, falsely elevates hematocrit) - High altitude living (baseline adaptation to lower oxygen) - Older age (less EPO regulatory efficiency)

What Hematocrit Numbers Actually Mean

Normal range: 38–48% in men (varies slightly by lab)

Optimal on TRT: Most physicians target ≤50% while on TRT

Flag zone: 52–54% — protocol adjustment warranted

High concern: 55%+ — dose pause and further evaluation

Polycythemia vera threshold: 48.5%+ (though polycythemia vera is a separate, rare clonal disorder — don't confuse TRT erythrocytosis with this disease)

The critical thing: a single elevated hematocrit reading is not a crisis. Hydration status, time of day, and recent alcohol intake all affect the reading. Re-test with proper hydration before making protocol changes based on a single value.

Protocol Adjustments That Lower Hematocrit

1. Reduce testosterone dose The most direct intervention — less testosterone means less EPO stimulation. A 10–20% dose reduction often brings hematocrit back into range. This should be done in consultation with your physician, with follow-up labs at 6–8 weeks.

2. Increase injection frequency Moving from once-weekly to twice-weekly injections (same total dose) reduces peak testosterone, which reduces the acute EPO stimulus. This is often enough to resolve elevated hematocrit without any dose reduction. The same total dose, delivered more evenly.

3. Switch to subcutaneous injection SubQ produces a flatter absorption curve with lower peaks. Multiple studies suggest lower hematocrit elevation with SubQ vs. IM at equivalent doses. This change alone has brought several patients' hematocrit from >52% to <50%.

4. Transition to topical testosterone Gels and creams produce the most physiologic absorption with the lowest peak-to-trough variation. They consistently produce less hematocrit elevation than injectable testosterone. The trade-off: absorption variability, transfer risk (to partners/children), and some patients simply prefer injections.

5. Address sleep apnea Undiagnosed or untreated sleep apnea is one of the most overlooked causes of TRT-associated erythrocytosis. Sleep apnea independently stimulates EPO through intermittent hypoxia. If your hematocrit is difficult to control, an overnight sleep study is worthwhile.

Therapeutic Phlebotomy: When to Donate Blood

Blood donation (standard blood bank donation or therapeutic phlebotomy) effectively and rapidly reduces hematocrit. A single unit donation typically drops hematocrit by 3–5 percentage points. This is:

• Safe and well-tolerated
• Immediately effective
• Beneficial from a blood donation standpoint (your blood is useful)
• Only a temporary fix if the underlying protocol isn't adjusted

The risk of relying solely on blood donation without protocol adjustment: you enter a cycle of recurring elevation requiring repeated donation. This can cause iron depletion over time (each donation removes iron stored in hemoglobin). If donating more than 3–4 times per year, monitor ferritin.

Most TRT physicians recommend phlebotomy as a bridging measure while making protocol changes, not as the primary long-term management strategy.

The Cardiovascular Risk Question

The traditional concern about elevated hematocrit is increased blood viscosity, which theoretically raises clot and stroke risk. This is theoretically sound but the actual clinical data specifically for TRT-induced erythrocytosis is less alarming than the warnings might suggest.

A 2020 review in the Journal of Clinical Endocrinology & Metabolism found that while TRT consistently increases hematocrit, the increase in cardiovascular events attributable specifically to TRT-induced erythrocytosis (as opposed to other cardiovascular risk factors) was not clearly established in men being treated appropriately with monitoring.

This is different from saying it doesn't matter — it does, and monitoring is essential. But the appropriate response to a hematocrit of 53% in a man on TRT is protocol adjustment and monitoring, not emergency treatment or permanent discontinuation.

Monitoring Schedule

For men on TRT: - Baseline labs before starting - Follow-up at 3 months (CBC including hematocrit) - Follow-up at 6 months - Annual monitoring once stable

If hematocrit is elevated at any follow-up, re-test in 2–4 weeks with proper hydration before making protocol changes. A single value is insufficient for a decision.

Marrow includes CBC monitoring with all TRT follow-up labs. Your physician reviews trends, not just single data points, and adjusts protocols based on the full clinical picture.

The Bottom Line

High hematocrit on TRT is the most manageable of the common TRT side effects. It's caused by a well-understood mechanism, corrected by evidence-based protocol adjustments, and monitored through routine labs. The solutions — reduced dose, higher frequency, SubQ switch, addressing sleep apnea — are available without stopping treatment.

What it requires is active monitoring and a physician who knows how to tune a TRT protocol rather than simply stopping it when labs look imperfect. Marrow's approach is protocol optimization, not reflexive discontinuation.